Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria
Phillip Wong(Monash Health), Frances Milat(Hudson Institute of Medical Research), Matthew T. Gillespie(Hudson Institute of Medical Research), Peter J. Fuller(Hudson Institute of Medical Research), Ian Larmour(Monash Health), Peter G. Kerr(Monash Health), James C.G. Doery(Monash Health), Donald K. Bowden(Monash Health), Kevan R. Polkinghorne(Monash Health)
Cited by 35
Related Papers
Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families
|Endocrine Reviews|1999|2.3k
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis
|Journal of Clinical Investigation|1999|1.7k
Comparison of Risk Prediction Using the CKD-EPI Equation and the MDRD Study Equation for Estimated Glomerular Filtration Rate
|JAMA|2012|991
Cystatin C versus Creatinine in Determining Risk Based on Kidney Function
|New England Journal of Medicine|2013|968
Breast Cancer Cells Interact with Osteoblasts to Support Osteoclast Formation1
|Endocrinology|1999|536